# Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Source: https://onco.cc/trials/nct05192798/  
OnCo record `nct05192798` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of nab-paclitaxel, rivoceranib (apatinib) and bevacizumab in triple-negative breast cancer, run by The First Affiliated Hospital of Bengbu Medical University, now recruiting.

## Summary

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC is a phase 2, randomised interventional study registered as NCT05192798 by The First Affiliated Hospital of Bengbu Medical University, with a registry enrolment figure of 128 participants, started 2022-01-14 and due to reach its primary completion in 2027-09-10. Interventions recorded: Albumin-Bound Paclitaxel; Apatinib Mesylate; Bevacizumab. Conditions listed: Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: "Patients with recurrent or metastatic triple negative breast cancer confirmed by histopathology and imaging;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05192798
- Phase: 2
- Setting: A Prospective, Randomized, Open Label Clinical Study Evaluating Efficacy and Safety of Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic Triple Negative Breast Cancer
- Sponsor: The First Affiliated Hospital of Bengbu Medical University
- Enrolled: 128

## Sources

- ClinicalTrials.gov NCT05192798: https://clinicaltrials.gov/study/NCT05192798

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Rivoceranib (apatinib)](https://onco.cc/drugs/rivoceranib/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05192798.json